Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Preoperative treatment with anastrozole reduces need for extensive surgery
April 6th, 2004
New data presented at EBCC 2004 indicate that preoperative (neoadjuvant) treatment with anastrozole (Arimidex; AstraZeneca) results in clinically beneficial reductions in tumor volume, extending the range of surgical options and allowing some patients to undergo less extensive surgery. Anastrozole, one of several selective aromatase inhibitors under study, has already been shown, through the 9,366 patient ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial, to provide significant efficacy benefits compared with tamoxifen, in addition to a more favorable overall tolerability profile in the adjuvant treatment of postmenopausal women with early breast cancer...
Source: Cancer Weekly (2004-04-06)
|
